Total trials
479
Active
23
Phase 3
86
Total enrollment
93,213
Pipeline matrix
Showing 40 of 46 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide | — | — | — | 11 | |||
| Rituximab | — | — | — | 20 | |||
| Dexamethasone | — | — | 37 | ||||
| Vincristine | — | — | — | 8 | |||
| Doxorubicin | — | — | — | 6 | |||
| Bortezomib | — | — | 9 | ||||
| Prednisone | — | — | — | 11 | |||
| Daratumumab | — | — | — | — | 8 | ||
| Golcadomide | — | — | — | 4 | |||
| BMS-986365 | — | — | — | — | 4 | ||
| Mezigdomide | — | — | — | 4 | |||
| Fludarabine | — | — | — | 4 | |||
| Bendamustine | — | — | — | — | 4 | ||
| ACE-536 | — | — | — | — | 2 | ||
| Lenalidomide | — | — | 58 | ||||
| Luspatercept | — | — | — | 9 | |||
| Docetaxel | — | — | — | — | 3 | ||
| Abiraterone | — | — | — | — | 2 | ||
| Iberdomide | — | — | — | — | 2 | ||
| idecabtagene vicleucel | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Predinsone/Prednisolone | — | — | — | — | — | 1 | |
| Prednisone/Prednisolone | — | — | — | — | — | 1 | |
| Epoetin alfa | — | — | — | — | — | 1 | |
| Gene-modified (GM) T cell therapy | — | — | — | — | — | 1 | |
| Pomalidomide | — | — | 30 | ||||
| BMS-986368 | — | — | — | — | 5 | ||
| Carfilzomib | — | — | — | — | 4 | ||
| CC-220 | — | — | — | — | 14 | ||
| CC-99282 | — | — | — | — | 4 | ||
| JCAR017 | — | — | — | — | 5 | ||
| Elotuzumab | — | — | — | — | 3 | ||
| Obinutuzumab | — | — | — | — | 5 | ||
| CC-92480 | — | — | — | — | 5 | ||
| Tafasitamab | — | — | — | — | — | 2 | |
| Elranatamab | — | — | — | — | — | 1 | |
| Valemetostat | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| AG-120 | — | — | — | — | — | 1 | |
| Daratumumab - 16mg/kg | — | — | — | — | — | 1 |
6 more active programs hidden
Next readouts
- 2018-08-02
- 2023-03-31
- 2024-05-09
- 2025-05-26
- 2025-08-11
- 2026-06-14
- 2026-11-23
- 2026-11-30
- 2027-01-10
- 2027-02-23
Top conditions
- Multiple Myeloma97
- Healthy Volunteers39
- Myelodysplastic Syndromes33
- Leukemia, Myeloid, Acute16
- Lymphoma, Non-Hodgkin16
- Neoplasms12
- Healthy Volunteer12
- Myelodysplastic Syndrome11
Frequently asked questions about Celgene
- How many clinical trials does Celgene have on ClinicalTrials.gov?
- Celgene is listed as the lead sponsor on 479 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Celgene's trials are in Phase 3?
- 86 of Celgene's trials are in Phase 3, spread across 46 active drug programs.
- What therapeutic areas does Celgene focus on?
- Celgene's most-studied conditions on ClinicalTrials.gov are Multiple Myeloma, Healthy Volunteers, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin.
- When are Celgene's next clinical trial readouts?
- Celgene has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy”, expected around 2018-08-02.